BACKGROUND: Ipsilateral breast recurrence or second primary breast cancer can develop in patients who have undergone breast conservation and sentinel lymph node biopsy (SLNB). This brings into question the necessity of complete axillary lymph node dissection (CALND) versus a second SLNB (remapping). Our objective is to determine the feasibility of a reoperative SLNB. STUDY DESIGN: A review of patients receiving a reoperative SLNB between April 1994 and December 2006 was conducted with IRB approval. Fifty-six patients underwent a second SLNB on the ipsilateral side an average of 42.5 months after their first SLNB. RESULTS: Sentinel lymph nodes were successfully remapped in 45 of 56 (80.4%) patients. Of 45 patients successfully remapped, 36 (80%) were node negative and were spared CALND. There was only 1 patient (2.2%) in whom a sentinel lymph node was identified outside of the ipsilateral axilla. At 26 months mean followup for the second SLNB, there have been no axillary recurrences and 1 death. CONCLUSIONS: Our findings demonstrate that remapping sentinel nodes in patients with ipsilateral recurrence or new primary breast cancer after SLNB achieved success in 80.4% of patients. Overall, 80.0% (36 of 45) of the successfully remapped patients were spared a CALND.
BACKGROUND: Ipsilateral breast recurrence or second primary breast cancer can develop in patients who have undergone breast conservation and sentinel lymph node biopsy (SLNB). This brings into question the necessity of complete axillary lymph node dissection (CALND) versus a second SLNB (remapping). Our objective is to determine the feasibility of a reoperative SLNB. STUDY DESIGN: A review of patients receiving a reoperative SLNB between April 1994 and December 2006 was conducted with IRB approval. Fifty-six patients underwent a second SLNB on the ipsilateral side an average of 42.5 months after their first SLNB. RESULTS: Sentinel lymph nodes were successfully remapped in 45 of 56 (80.4%) patients. Of 45 patients successfully remapped, 36 (80%) were node negative and were spared CALND. There was only 1 patient (2.2%) in whom a sentinel lymph node was identified outside of the ipsilateral axilla. At 26 months mean followup for the second SLNB, there have been no axillary recurrences and 1 death. CONCLUSIONS: Our findings demonstrate that remapping sentinel nodes in patients with ipsilateral recurrence or new primary breast cancer after SLNB achieved success in 80.4% of patients. Overall, 80.0% (36 of 45) of the successfully remapped patients were spared a CALND.
Authors: Lenka Vermeeren; Willem Meinhardt; Henk G van der Poel; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-09 Impact factor: 9.236
Authors: Diego A Vicente; Leonard R Henry; George Hahm; Peter W Soballe; DeeDee Smart Journal: World J Surg Oncol Date: 2010-07-09 Impact factor: 2.754
Authors: Pablo Borrelli; Maarten L Donswijk; Marcel P Stokkel; Suzana C Teixeira; Harm van Tinteren; Emiel J Th Rutgers; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2016-10-27 Impact factor: 9.236
Authors: Ingrid G M Poodt; Guusje Vugts; Adriana J G Maaskant-Braat; Robert-Jan Schipper; Adri C Voogd; Grard A P Nieuwenhuijzen Journal: Ann Surg Oncol Date: 2018-03-01 Impact factor: 5.344